March 11, 2020 / 8:51 PM / in a month

BRIEF-Clearside Biomedical Announces License Agreement With Arctic Vision For Xipere™ In Greater China And South Korea

March 11 (Reuters) - Clearside Biomedical Inc:

* CLEARSIDE BIOMEDICAL ANNOUNCES LICENSE AGREEMENT WITH ARCTIC VISION FOR XIPERE™ (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION) IN GREATER CHINA AND SOUTH KOREA

* CLEARSIDE BIOMEDICAL INC - CLEARSIDE ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS AND ROYALTIES ON PRODUCT SALES

* CLEARSIDE BIOMEDICAL INC - CLEARSIDE ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS AND ROYALTIES ON PRODUCT SALES

* CLEARSIDE BIOMEDICAL - ARCTIC VISION TO LEAD EXPANSION OF NOVEL APPROACH TO TREATING MACULAR EDEMA ASSOCIATED WITH UVEITIS IN ASIA

* CLEARSIDE BIOMEDICAL - CLEARSIDE MAY RECEIVE UP TO $35.5 MILLION IN DEVELOPMENT AND SALES MILESTONES

* CLEARSIDE BIOMEDICAL INC - AMOUNT INCLUDES A $4.0 MILLION UPFRONT PAYMENT PLUS ADDITIONAL MILESTONE PAYMENTS

* CLEARSIDE BIOMEDICAL - WILL BE ENTITLED TO RECEIVE TIERED ROYALTIES OF 10% TO 12% BASED ON ANNUAL NET SALES OF XIPERE

* CLEARSIDE BIOMEDICAL - ARCTIC VISION MAY PURSUE DEVELOPMENT, COMMERCIALIZATION OF XIPERE IN GREATER CHINA, SOUTH KOREA WITH CONSENT FROM CLEARSIDE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below